Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04452487
Other study ID # 2020_GUASTELLA_COVID-19-LAT
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 1, 2020
Est. completion date June 2021

Study information

Verified date June 2020
Source University Hospital, Clermont-Ferrand
Contact Lise LACLAUTRE
Phone +33473754963
Email promo_interne_drci@chu-clermontferrand.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This survey is performed to examine if during the Covid's crisis, the practitionner's have respected the modalities of the law about the end of life, in particular concerning limitations and stop of therapeutics


Description:

In the current legislativ context notably the Clayes Leonetti law, a very large majority of ICU (Intensive Care Unit) patients die with the establishement of a procedure for the limitation and cessation of therapeutics (LAT). During a viral pandemic, medical resources can be saturated, limiting reflexive abilities in favour of binary decisions. This sorting of patients leads to LAT that could be performed without the elementary modalities stated by the law. Thus, arbitrary medical decisions made alone could expose patients to unjustified " loss of luck ". Increasing the resources mobilized during a pandemic must not make us forget the quality of care provided for the benefit of quantity. In therefore seems legitimate to keep the LAT modalities to ensure our ethical principles. No work in the literature based on actual facts explores the impact of a pandemic on compliance with and maintenance of ethical principles and the legisltaive framework, in particular as regards the procedures of the application of LAT.

The purpose of this study is to assess whether the terms of the LAT are being complied during a pandemic for patients with or without Covid.


Recruitment information / eligibility

Status Recruiting
Enrollment 2500
Est. completion date June 2021
Est. primary completion date June 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Hospitalized major patient

- Infected or not with Covid-19

- having a management with a LAT defined by an anticipated or factual restriction of a therapeutic resource ( organ replacement, specific treatment) while his or her state of health requires or may require it, leading or not a death. The patient's death occurs either after a cariac massagewhich corresponds to a maximum management with therapeutic failure or within the framework or in the context of brain death, in these cases there is no LAT ; either without cardiac massage and in this case there is de facto a LAT wether or not it is performed according to legisltaive procedures. All patients who die will beclassified according to this diagram for the inclusion criterion. For surviving patients, an analysis of the record in search of LAT elments will be performed. In the absence of LAT elment in the record, i twill be considered that the patient did not have LAT and therfore will not be included.

Exclusion Criteria:

None

Study Design


Related Conditions & MeSH terms

  • Communicable Diseases
  • Infection
  • Patient Hopsitalized in Internal Medicine Unit
  • Patient Hospitalized in Disease Infectious Unit
  • Patient Hospitalized in Intensive Reanimation Unit

Intervention

Behavioral:
decisions of limitations and stop processing
Compliance of the modalities of decisions of limitations and stop processing

Locations

Country Name City State
France CHU de Clermont-Ferrand Clermont-Ferrand
France Hospices Civiles de Lyon Lyon
France CH de Vichy Vichy

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Clermont-Ferrand

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary decisions of limitations and therapeutic stops The conformity of the modalities of the decisions of limitations and therapeutic stops will be evaluated by a composite criterion defined by the simultaneous presence of the 3 main modalities imposed by the Clayes-Leonetti law to achieve a limitation that are : An outside consultant's opinion ( required if no advance directives), the caregiver collegial discussion or adherence to patient advance directives, notification of decision in the medical record at the end of patient's hospitalization, an average of one month
Secondary Characteristics of the notification of LAT procedure notification of the decision, the conclusions of the discussions, the opinion of the consultant and the arguments given to justify the LAT at the end of patient's hospitalization, an average of one month
Secondary Characteristics of the LAT procedure (persons who participated to the collegial discussion) number and status of caregivers who participated to the collegial discussion at the end of patient's hospitalization, an average of one month
Secondary Characteristics of consultant's reasoned opinion for the LAT procedure formal elements of the consultant's reasoned opinion ( legal term) in the file at the end of patient's hospitalization, an average of one month
Secondary Characteristics of the LAT procedure formal elements of advance directives at the end of patient's hospitalization, an average of one month
Secondary Characteristics of units number of beds, number of caregivers (medical, paramedical, internal external), number of admissions during periods of study day 0
Secondary Age of physicians measured in year Day 0
Secondary gendrer of physicians male or female Day 0
Secondary Exparience of physicians Measured in year of experience Day 0
Secondary Characteristics of physicians professional status Day 0
Secondary Age of patients measured in year day 0
Secondary patient's history comorbidities day 0
Secondary COVID-19 patient's status COVID19 infection (yes or no) day 0
Secondary Characteristics of hospitalization's patients hospitalization reason day 0
Secondary Characteristics of affected organ organ failure day 0
Secondary Characteristics of patients severity score day 0
Secondary final patient status fate day 0
Secondary patient's environnement family presence or relatives day 0